The rise of Viagra initially fueled a surge for pharma, however recent changes present a murky outlook for shareholders. Off-patent versions are reducing revenue, and persistent legal battles add more risk to the https://antonwqlw962089.blogsidea.com/47979021/the-blue-pill-and-the-pharmaceutical-industry-a-risky-bet